



CLAIMS

1. A compound corresponding to formula (I):




in which:


- n represents 0 or 1;
- Y represents a bridged morpholine chosen from



(a)



(b)



(c)

➤ L represents a linker $-\text{CH}_2-\text{CO}-$ such that the carbonyl function is attached to the substituent R_1 , or a (C_1-C_2) alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3) alkyl group and a hydroxyl group;

➤ R_1 represents:

- a linear, branched, cyclic or partially cyclic (C_1-C_5) alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group, an aryl group and a trifluoromethyl group,
- a (C_3-C_6) cycloalkyl group, optionally substituted with a hydroxyl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, a cyano group, an $-\text{NH}_2$ group, a urea group of formula $-\text{NH}-\text{CO}-\text{NH}-(\text{C}_1-\text{C}_4)$ alkyl, a morpholine group, a group of formula $-\text{SO}_2-(\text{C}_1-\text{C}_5)$ alkyl, a (C_1-C_5) alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:

- a halogen atom,

- a hydroxyl group or a (C₁-C₅)alkoxy group,
- a group -COR₃, in which R₃ represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
- a group -CONR₄R_{4'} in which R₄ and R_{4'} are as defined below,
- a group -NR₄R_{4'} in which R₄ and R_{4'} are as defined below,
- a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
- a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group;
- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
 - a halogen atom,
 - a (C₁-C₃)alkyl group optionally substituted with one or more halogen atoms,
 - a (C₁-C₅)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C₃-C₅)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group,
 - a group -NR₅R_{5'} in which R₅ and R_{5'}, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO₂-(C₁-C₃)alkyl group, a (C₃-C₅)cycloalkyl group and a linear or branched (C₁-C₃)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
- a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
- a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO₂-(C₁-C₄)alkyl group,
- a group -NR₆R_{6'} in which R₆ and R_{6'}, which are different, represent a (C₁-C₅)alkyl group and a (C₁-C₅)alkoxy group,
- R₂ represents a hydrogen atom when n represents 1 and a methyl group when


n represents 0;

➤ R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1 - C_3)alkyl group, in the form of the base or of an addition salt with an acid or with a base.


5

2. The compound of formula (I) as claimed in claim 1, characterized in that:


- n represents 0 or 1;
- Y represents a bridged morpholine chosen from



(a)



(b)



(c)

10

➤ L represents a linker $-CH_2-CO-$ such that the carbonyl function is attached to the substituent R_1 , or a (C_1 - C_2)alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1 - C_3)alkyl group and a hydroxyl group;

15

➤ R_1 represents:

- a linear or branched (C_1 - C_5) alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group and an aryl group,
- a (C_3 - C_6)cycloalkyl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, a cyano group, an $-NH_2$ group, a urea group of formula $-NH-CO-NH-(C_1-C_4)$ alkyl, a morpholine group, a group of formula $-SO_2-(C_1-C_5)$ alkyl, a (C_1 - C_5)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:

20

- a halogen atom,
- a hydroxyl group or a (C_1 - C_5)alkoxy group,
- a group $-COR_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
- a group $-CONR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
- a group $-NR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
- a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,

25


30

- a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group;
- 5 - a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
 - a halogen atom,
 - a (C₁-C₃)alkyl group optionally substituted with one or more halogen atoms,
 - 10 ○ a (C₁-C₅)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C₃-C₅)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group,
 - 15 ○ a group -NR₅R₅ in which R₅ and R₅, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO₂-(C₁-C₃)alkyl group, a (C₃-C₅)cycloalkyl group and a linear or branched (C₁-C₃)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
 - 20 - a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
 - a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group and an acetyl group,
 - 25 - a group -NR₆R₆ in which R₆ and R₆, which are different, represent a (C₁-C₅)alkyl group and a (C₁-C₅)alkoxy group,
 - R₂ represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;
 - 30 ➤ R₄ and R₄, independently, which may be identical or different, represent a hydrogen atom or a (C₁-C₃)alkyl group,

in the form of the base or of an addition salt with an acid or with a base.

3. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

- 35 ➤ Y represents a bridged morpholine (a)




(a)

in the form of the base or of an addition salt with an acid or with a base.

4. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

5

- n represents 0 or 1;
- Y represents a bridged morpholine (a)



(a)

10

➤ L represents a linker $-\text{CH}_2\text{-CO}-$ such that the carbonyl function is attached to the substituent R_1 , or $(\text{C}_1\text{-C}_2)\text{alkyl}$, said alkyl being optionally substituted with one or more substituents chosen from a $(\text{C}_1\text{-C}_3)\text{alkyl}$ group;

15

➤ R_1 represents:

- a linear, branched, cyclic or partially cyclic $(\text{C}_1\text{-C}_5)\text{alkyl}$ group, optionally substituted with one or more substituents chosen from a hydroxyl group, an aryl group, a trifluoromethyl group and a $(\text{C}_3\text{-C}_6)\text{cycloalkyl}$ group,
- a $(\text{C}_3\text{-C}_6)\text{cycloalkyl}$ group, optionally substituted with a hydroxyl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, an $-\text{NH}_2$ group, a urea group of formula $-\text{NH}-\text{CO}-\text{NH}-(\text{C}_1\text{-C}_4)\text{alkyl}$, a morpholinyl group, a group of formula $-\text{SO}_2-(\text{C}_1\text{-C}_5)\text{alkyl}$, a $(\text{C}_1\text{-C}_5)\text{alkoxy}$ group, said alkoxy being optionally substituted with one or more substituents chosen from:

20

- a halogen atom,
- a hydroxyl group or a $(\text{C}_1\text{-C}_5)\text{alkoxy}$,
- a group $-\text{COR}_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
- a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
- a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a $(\text{C}_1\text{-C}_3)\text{alkyl}$ group, a hydroxyl group and


25

an -NH₂ group;

- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
 - 5 ○ a halogen atom,
 - a (C₁-C₃)alkyl group optionally substituted with one or more halogen atoms,
 - a (C₁-C₅)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C₃-C₅)cycloalkyl group, a
 - 10 heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group,
 - a group -NR₅R_{5'} in which R₅ and R_{5'}, independently, which may be identical or different, represent a substituent chosen from a hydrogen
 - 15 atom, a -CO₂-(C₁-C₃)alkyl group, a (C₃-C₅)cycloalkyl group and a linear or branched (C₁-C₃)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
 - a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an
 - 20 oxygen atom,
 - a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO₂-(C₁-C₄)alkyl group,
 - 25 - a group -NR₆R_{6'} in which R₆ and R_{6'}, which are different, represent a (C₁-C₅)alkyl group and a (C₁-C₅)alkoxy group,
 - R₂ represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;
 - R₄ and R_{4'}, independently, which may be identical or different, represent a
 - 30 hydrogen atom or a (C₁-C₃)alkyl group,
- in the form of the base or of an addition salt with an acid or with a base.

5. The compound of formula (I) as claimed in any one of claims 1 to 4, characterized in that:

- 35 ➤ n represents 0 or 1;
- Y represents a bridged morpholine (a)



(a)

➤ L represents a linker $-\text{CH}_2-\text{CO}-$ such that the carbonyl function is attached to the substituent R_1 , or (C_1-C_2) alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3) alkyl group;

➤ R_1 represents:

- a linear, branched, cyclic or partially cyclic (C_1-C_5) alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group and an aryl group,
- a (C_3-C_6) cycloalkyl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, an $-\text{NH}_2$ group, a urea group of formula $-\text{NH}-\text{CO}-\text{NH}-(\text{C}_1-\text{C}_4)$ alkyl, a morpholinyl group, a group of formula $-\text{SO}_2-(\text{C}_1-\text{C}_5)$ alkyl, a (C_1-C_5) alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
 - a halogen atom,
 - a hydroxyl group or a (C_1-C_5) alkoxy,
 - a group $-\text{COR}_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
 - a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
 - a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3) alkyl group, a hydroxyl group and an $-\text{NH}_2$ group,
- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
 - a halogen atom,
 - a (C_1-C_3) alkyl group optionally substituted with one or more halogen atoms,
 - a (C_1-C_5) alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C_3-C_5) cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents

chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group,

5 ○ a group -NR₅R_{5'} in which R₅ and R_{5'}, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO₂-(C₁-C₃)alkyl group, a (C₃-C₅)cycloalkyl group and a linear or branched (C₁-C₃)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,

10 - a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,

10 - a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group and an acetyl group,

15 - a group -NR₆R_{6'} in which R₆ and R_{6'}, which are different, represent a (C₁-C₅)alkyl group and a (C₁-C₅)alkoxy group,

➤ R₂ represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;

➤ R₄ and R_{4'}, independently, which may be identical or different, represent a hydrogen atom or a (C₁-C₃)alkyl group,


20 in the form of the base or of an addition salt with an acid or with a base.

6. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:


➤ n represents 0 or 1;

➤ Y represents a bridged morpholine chosen from (b) and (c)

25



(b)



(c)

30 ➤ L represents a linker -CH₂-CO- such that the carbonyl function is attached to the substituent R₁, or (C₁-C₂)alkyl, said alkyl being optionally substituted with a hydroxyl group;

➤ R₁ represents:

- a linear or branched (C₁-C₅)alkyl group, optionally substituted with an aryl group,
 - an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group and a (C₁-C₅)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
 - a group -CONR₄R_{4'} in which R₄ and R_{4'} are as defined below,
 - a group -NR₄R_{4'} in which R₄ and R_{4'} are as defined below,
 - a heteroaryl group comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more (C₁-C₃)alkyl groups, optionally substituted with one or more halogen atoms,
 - R₂ represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;
 - R₄ and R_{4'}, independently, which may be identical or different, represent a hydrogen atom or a (C₁-C₃)alkyl group,
- in the form of the base or of an addition salt with an acid or with a base.

7. The compound as claimed in any one of claims 1 to 6, characterized in that the linker L represents -CH₂-CO, in the form of the base or of an addition salt with an acid or with a base.

8. The compound as claimed in any one of claims 1 to 7, characterized in that n represents 1, in the form of the base or of an addition salt with an acid or with a base.

9. The compound as claimed in any one of claims 1 to 7, characterized in that n represents 0, in the form of the base or of an addition salt with an acid or with a base.

10. The compound as claimed in any one of claims 1 to 9, characterized in that R₁ represents a heteroaryl group, in the form of the base or of an addition salt with an acid or with a base.

11. The compound as claimed in any one of claims 1 to 9, characterized in that R₁ represents a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO₂-(C₁-C₄)alkyl group, in the form of the base or of an addition salt with an acid or with a base.

12. The compound as claimed in any one of the preceding claims 1 to 11, characterized in that it is chosen from:

- 1 (8S)-9-(2-Methyl-2-pyrid-4-ylpropyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 2 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 3 (8S)-9-[2-(6-Aminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 4 (8S)-9-[2-(6-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5 (8S)-9-[2-(6-Methylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 6 (8S)-9-[2-(6-Dimethylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 7 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 8 1-[2-(6-Dimethylaminopyrid-3-yl)-2-oxoethyl]-2-(S)-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 9 2-(S)-Methyl-1-[2-(6-methylaminopyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 10 (8S)-1-[2-(4-Methoxyphenyl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-

- azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 11 (S)-1-[2-(6-Aminopyrid-3-yl)-2-oxoethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 5
- 12 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 13 2-Methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1-(2-pyrid-3-ylethyl)-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 10 14 (8S)-9-{2-[6-(2-Hydroxyethylamino)pyrid-3-yl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 15 (8S)-9-[2-(5-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 16 2-Methyl-1-[2-(5-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 17 2-Methyl-1-[2-(6-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 20 20 azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 18 2-Methyl-1-[2-(2-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 25 19 (8S)-9-[2-(2-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 (8S)-9-[2-(4-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-

4-one

- 21 2-Methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1-(2-oxo-2-pyrid-3-yl)ethyl)-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 5 22 (8S)-9-[2-(6-Cyclopropylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 23 1-Ethyl-3-{4-[2-((S)-8-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)ethyl]phenyl}urea
- 10 24 1-Ethyl-3-{4-[2-((S)-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-5-oxo-2-trifluoromethyl-2,3-dihydro-5H-imidazo[1,2-a]pyrimidin-1-yl)ethyl]phenyl}urea
- 25 (8S)-9-[2-(4-Methylthiazol-5-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 26 2-Methyl-1-[2-(4-methylthiazol-5-yl)ethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 27 (8S)-9-[2-(3,5-Dimethyl-1H-pyrazol-4-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 28 1-[2-(3,5-Dimethyl-1H-pyrazol-4-yl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 29 (8S)-9-(3,3-Dimethyl-2-oxobutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 25 30 1-(3,3-Dimethyl-2-oxobutyl)-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 31 (8S)-9-[2-(6-Amino-5-methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 32 1-[2-(4-Aminophenyl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 33 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(6-trifluoromethylpyrid-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 34 (8S)-9-(2-{6-[(2-Hydroxyethyl)methylamino]pyrid-3-yl}-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 35 (8S)-9-[2-(6-Ethoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 36 (8S)-9-[2-(6-Amino-4,5-dimethylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 37 (S)-9-[2-(4-Difluoromethoxyphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 38 (8S)-9-[2-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 39 (8S)-9-[2-(4-Methyloxazol-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 40 (S)-9-[2-(3,4-Difluorophenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 41 (8S)-9-[2-(4-Morpholin-4-ylphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 42 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]benzonitrile
- 43 (8S)-9-[2-(4-Methylthiazol-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 44 (8S)-9-[2-(5-Chloropyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 45 (8S)-9-[2-(6-Methoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 46 (8S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 47 (8S)-9-(2-Benzo[1,2,3]thiadiazol-5-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 48 (8S)-9-[2-(2,4-Difluorophenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 49 (8S)-9-(3-Ethyl-3-hydroxypentyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 50 (8S)-9-(3-Hydroxy-3-methylbutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 51 (8S)-9-(1-Methyl-1H-indazol-3-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 52 (8S)-9-[2-(2-Cyclopropylmethoxypyrimidin-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 53 (8S)-9-[2-(3,5-Dimethylisoxazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 54 (8S)-9-(2-Ethyl-2-hydroxybutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 55 3-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]benzonitrile
- 56 (8S)-9-(3-Methyl-2-oxobutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 10 57 {5-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]pyrid-2-yl}carbamic acid ethyl ester
- 58 {5-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]pyrid-2-yl}carbamic acid methyl ester
- 15 59 (8S)-9-(5-Methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 60 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(2-trifluoromethylpyrid-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 61 (8S)-9-(2-Benzo[1,2,5]thiadiazol-5-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 25 62 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 63 (8S)-9-{2-[6-(2-Fluoroethoxy)pyrid-3-yl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 64 (8S)-9-{2-[3-Fluoro-4-(2-fluoroethoxy)phenyl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5 65 (8S)-9-[2-(2-Methoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 66 (8S)-9-[2-(3-Methyl-3H-imidazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 10 67 (8S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 68 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 69 (8S)-9-[2-(2-Methyl-2H-pyrazol-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 70 N,N-Dimethyl-2-(4-{2-[(S)-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-5-oxo-2-trifluoromethyl-2,3-dihydro-5H-imidazo[1,2-a]pyrimidin-1-yl]ethyl}phenoxy)acetamide
- 20 71 (8S)-9-[(S)-2-(4-Fluoro-2-methoxyphenyl)-2-hydroxyethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 72 (2S)-1-[2-(4-Hydroxyphenyl)ethyl]-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 25 73 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-phenylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 74 (2S)-1-{2-[4-(2-Dimethylaminoethoxy)phenyl]ethyl}-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one

- 75 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyrid-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 76 (S)-1-[2-(4-Methoxyphenyl)ethyl]-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 5 77 (S)-2-Methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1-(3-phenylpropyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 78 (S)-1-{2-[4-(3-Dimethylaminopropoxy)phenyl]ethyl}-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 10 79 (2S)-1-((S)-2-Hydroxy-2-phenylethyl)-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 80 (8S)-9-((S)-2-Hydroxy-2-phenylethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 81 (8S)-9-[2-(4-Methoxyphenyl)ethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 82 (8S)-9-((R)-2-Benzo[b]thiophen-2-yl-2-hydroxyethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 83 (8S)-9-[2-(4-Hydroxyphenyl)ethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 84 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(3-phenylpropyl)-8-trifluoromethylmethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 85 (8S)-2-(3-Oxa-8-azabicyclo[3.2.1]oct-8-yl)-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 25 86 (8S)-9-(1-Difluoromethyl-1H-pyrazol-3-ylmethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 87 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 88 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyrid-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5 89 (S)-9-[2-(1-Acetylpiperid-4-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 90 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)ethyl]piperidine-1-carbaldehyde
- 91 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]piperidine-1-carboxylic acid
10 ethyl ester
- 92 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 93 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(tetrahydropyran-4-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
15
- 94 (8S)-9-(1-Acetylpiperid-4-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 95 4-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-ylmethyl)piperidine-1-carbaldehyde
- 20 96 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(3,3,3-trifluoro-2-hydroxy-2-trifluoromethylpropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 97 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(4,4,4-trifluoro-3-hydroxy-3-trifluoromethylbutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
25
- 98 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 99 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5 100 (8S)-9-[2-(1-Hydroxycyclopentyl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 101 (8S)-9-(1-Hydroxycyclopentylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 10 102 (8S)-9-(3,3-Dicyclopropyl-3-hydroxypropyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 103 (8S)-9-(2,2-Dicyclopropyl-2-hydroxyethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 104 (8S)-9-(1-Hydroxycyclopropylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 105 (8S)-9-[2-(1-Hydroxycyclopropyl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 106 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-quinolin-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 107 (8S)-9-[2-(3-Methylisothiazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 25 108 (8S)-9-[2-(4-Methanesulfonylphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 109 (8S)-9-Isoquinolin-5-ylmethyl-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 110 (8S)-9-(2-Morpholin-4-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-


yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 111 (8S)-9-{2-[4-(2-Morpholin-4-ylethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5 112 N-Methoxy-N-methyl-2-((S)-8-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetamide
- 113 (8S)-9-(2-Imidazo[1,2-a]pyrid-6-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 10 114 (8S)-9-[2-(6-Difluoromethoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 115 (S)-9-{2-[4-(2-Morpholin-4-yl-2-oxoethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 116 (8S)-9-(1-Methyl-3-trifluoromethyl-1H-pyrazol-4-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 117 (8S)-9-{2-[4-(2-Dimethylaminoethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 118 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]piperidine-1-carbaldehyde
- 25 119 (8S)-9-[2-(1-Acetylpiperid-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one


in the form of the base or of an addition salt with an acid or with a base.

13. A process for preparing a compound of formula (I) as claimed in any one of claims

1 to 12, comprising the reaction of a compound of formula E




in which n represents 0 or 1 and R₂ represents a hydrogen atom when n = 1 or a methyl group when n = 0, with a bridged morpholine Y, chosen from (a), (b) and (c) as defined in claim 1, to obtain a compound of formula I




and the alkylation reaction by addition to I of a compound of formula J = R₁-L-Lg in which R₁ and L are as defined in any one of the preceding claims and Lg is a leaving group.

14. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, comprising the alkylation reaction of a compound of formula E




in which n represents 0 or 1 and R₂ represents a hydrogen atom when n = 1 or a methyl group when n = 0, by addition of a compound of formula J = R₁-L-Lg in which R₁ and L are as defined in any one of claims 1 to 8 and Lg is a leaving group, to obtain a compound of formula K



in which R₁, R₂, L and n are as defined in one of claims 1 to 8, and a reaction on a


compound K with a compound of formula Y being a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1.

15. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is an ethyl group, R_1 is a linear or branched (C_1 - C_5)alkyl group substituted with a hydroxyl group, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when $n = 1$ and a methyl group when $n = 0$, comprising a Michael addition reaction of a compound of formula E



10

in which n represents 0 or 1 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$, on a compound of formula $M = CH_2=CH_2-CO_2Alkyl$, to obtain a compound of formula N,




- 15 in which n represents 0 or 1 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$, and Y is a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1,

and a reaction of alkyl on a compound of formula N with a compound of formula $O = Z-Mg-X$ in which Z represents a linear or branched alkyl radical and X is a halogen atom.

20


16. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is a methyl group, R_1 is a linear or branched (C_1 - C_5)alkyl group substituted with a hydroxyl group, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when $n = 1$ and a methyl group when $n = 0$, comprising an addition reaction of a compound of formula E

25



in which n represents 0 or 1 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$, with a compound of formula $P = X-CH_2-CO_2Alkyl$ with X being a halogen atom, to obtain a compound of formula Q

5




in which Y is a bridged morpholine chosen from (a), (b) and (c), n represents 0 or 1 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$,

and an alkylation reaction on a compound of formula Q with a compound of formula $O = Z-Mg-X$ in which Z represents a linear or branched alkyl radical and X is a halogen atom.

10


17. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is a methyl group, R_1 is a group $-NR_6R_6'$ with R_6 et R_6' being either different and representing an alkyl group and an alkoxy group, or R_6 and R_6' together forming a monocyclic or bicyclic heterocycloalkyl, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when $n = 1$ and a methyl group when $n = 0$, comprising a hydrolysis reaction of a compound of formula Q

20




in which Y is a bridged morpholine chosen from (a), (b) and (c), n represents 0 or 1 and

R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$, to obtain a compound of formula S



in which Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$, and a coupling reaction between a compound of formula S and a compound of formula HNR_6R_6' with R_6 and R_6' being either different and representing an alkyl group and an alkoxy group, or R_6 and R_6' together forming a monocyclic or bicyclic heterocycloalkyl.

18. Compounds of formulae I, N, Q and S:



in which n , R_2 and Y are as defined in claim 1.

19. A medicament, characterized in that it comprises a compound as claimed in any one of claims 1 to 12, or an addition salt of this compound with a pharmaceutically acceptable acid or base.

20. The compound as claimed in any one of claims 1 to 12, as a medicament.

21. A pharmaceutical composition, characterized in that it comprises a compound as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable salt of this compound, and also at least one pharmaceutically acceptable excipient.

5

22. The use of a compound as claimed in any one of claims 1 to 12, for the preparation of a medicament for treating parasite-induced malaria.


10

23. The compound as claimed in any one of claims 1 to 12, for its use in the treatment of malaria induced by all species of *Plasmodium*, such as *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale* and *P. knowlesi*, by all species of *Trypanosoma* and by all species of *Leishmania*, in the treatment of sleeping sickness, the treatment of Chagas disease, the various forms of leishmaniasis and the treatment of other parasitic infections, such as schistosomiasis (bilharzia), toxoplasmosis and coccidiosis.

15

CLAIMS


1. A compound corresponding to formula (I):




5

in which:


- n represents 0 or 1;
- Y represents a bridged morpholine chosen from



(a)



(b)



(c)

10

➤ L represents a linker $-\text{CH}_2\text{-CO}-$ such that the carbonyl function is attached to the substituent R_1 , or a $(\text{C}_1\text{-C}_2)$ alkyl, said alkyl being optionally substituted with one or more substituents chosen from a $(\text{C}_1\text{-C}_3)$ alkyl group and a hydroxyl group;

15

➤ R_1 represents:

- a linear, branched, cyclic or partially cyclic $(\text{C}_1\text{-C}_5)$ alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group, an aryl group and a trifluoromethyl group,
- a $(\text{C}_3\text{-C}_6)$ cycloalkyl group, optionally substituted with a hydroxyl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, a cyano group, an $-\text{NH}_2$ group, a urea group of formula $-\text{NH-CO-NH-}(\text{C}_1\text{-C}_4)\text{alkyl}$, a morpholine group, a group of formula $-\text{SO}_2\text{-(C}_1\text{-C}_5)\text{alkyl}$, a $(\text{C}_1\text{-C}_5)$ alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:

25

- a halogen atom,

- a hydroxyl group or a (C₁-C₅)alkoxy group,
- a group -COR₃, in which R₃ represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
- a group -CONR₄R_{4'} in which R₄ and R_{4'} are as defined below,
- 5 ○ a group -NR₄R_{4'} in which R₄ and R_{4'} are as defined below,
- a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
- a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and
- 10 an -NH₂ group;
- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
 - a halogen atom,
 - 15 ○ a (C₁-C₃)alkyl group optionally substituted with one or more halogen atoms,
 - a (C₁-C₅)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C₃-C₅)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents
 - 20 chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group,
 - a group -NR₅R_{5'} in which R₅ and R_{5'}, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO₂-(C₁-C₃)alkyl group, a (C₃-C₅)cycloalkyl group and a linear or branched (C₁-C₃)alkyl group, said alkyl group being optionally
 - 25 substituted with one or more hydroxyl groups,
- a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
- 30 - a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO₂-(C₁-C₄)alkyl group,
- a group -NR₆R_{6'} in which R₆ and R_{6'}, which are different, represent a (C₁-C₅)alkyl group and a (C₁-C₅)alkoxy group,
- 35 ➤ R₂ represents a hydrogen atom when n represents 1 and a methyl group when


n represents 0;

➤ R_4 and $R_{4'}$, independently, which may be identical or different, represent a hydrogen atom or a (C_1-C_3) alkyl group, in the form of the base or of an addition salt with an acid or with a base.

5

2. The compound of formula (I) as claimed in claim 1, characterized in that:

- n represents 0 or 1;
- Y represents a bridged morpholine chosen from



10

➤ L represents a linker $-CH_2-CO-$ such that the carbonyl function is attached to the substituent R_1 , or a (C_1-C_2) alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3) alkyl group and a hydroxyl group;

15

➤ R_1 represents:

- a linear or branched (C_1-C_5) alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group and an aryl group,
- a (C_3-C_6) cycloalkyl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, a cyano group, an $-NH_2$ group, a urea group of formula $-NH-CO-NH-(C_1-C_4)$ alkyl, a morpholine group, a group of formula $-SO_2-(C_1-C_5)$ alkyl, a (C_1-C_5) alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:

20

25


- a halogen atom,
- a hydroxyl group or a (C_1-C_5) alkoxy group,
- a group $-COR_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
- a group $-CONR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
- a group $-NR_4R_{4'}$ in which R_4 and $R_{4'}$ are as defined below,
- a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,

30

- a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group;
 - 5 - a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
 - a halogen atom,
 - a (C₁-C₃)alkyl group optionally substituted with one or more halogen atoms,
 - 10 ○ a (C₁-C₅)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C₃-C₅)cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group,
 - 15 ○ a group -NR₅R_{5'} in which R₅ and R_{5'}, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO₂-(C₁-C₃)alkyl group, a (C₃-C₅)cycloalkyl group and a linear or branched (C₁-C₃)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
 - 20 - a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
 - a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group and an acetyl group,
 - 25 - a group -NR₆R_{6'} in which R₆ and R_{6'}, which are different, represent a (C₁-C₅)alkyl group and a (C₁-C₅)alkoxy group,
 - R₂ represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;
 - 30 ➤ R₄ and R_{4'}, independently, which may be identical or different, represent a hydrogen atom or a (C₁-C₃)alkyl group,
- in the form of the base or of an addition salt with an acid or with a base.

3. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

- 35 ➤ Y represents a bridged morpholine (a)




(a)

in the form of the base or of an addition salt with an acid or with a base.

4. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

- 5 ➤ n represents 0 or 1;
 ➤ Y represents a bridged morpholine (a)



(a)

- 10 ➤ L represents a linker $-\text{CH}_2\text{-CO}-$ such that the carbonyl function is attached to the substituent R_1 , or $(\text{C}_1\text{-C}_2)\text{alkyl}$, said alkyl being optionally substituted with one or more substituents chosen from a $(\text{C}_1\text{-C}_3)\text{alkyl}$ group;


- R_1 represents:
- a linear, branched, cyclic or partially cyclic $(\text{C}_1\text{-C}_5)\text{alkyl}$ group, optionally substituted with one or more substituents chosen from a hydroxyl group, an aryl group, a trifluoromethyl group and a $(\text{C}_3\text{-C}_6)\text{cycloalkyl}$ group,
 - a $(\text{C}_3\text{-C}_6)\text{cycloalkyl}$ group, optionally substituted with a hydroxyl group,
 - an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, an $-\text{NH}_2$ group, a urea group of formula $-\text{NH}-\text{CO}-\text{NH}-(\text{C}_1\text{-C}_4)\text{alkyl}$, a morpholinyl group, a group of formula $-\text{SO}_2-(\text{C}_1\text{-C}_5)\text{alkyl}$, a $(\text{C}_1\text{-C}_5)\text{alkoxy}$ group, said alkoxy being optionally substituted with one or more substituents chosen from:
 - a halogen atom,
 - a hydroxyl group or a $(\text{C}_1\text{-C}_5)\text{alkoxy}$,
 - a group $-\text{COR}_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
 - a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
 - a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a $(\text{C}_1\text{-C}_3)\text{alkyl}$ group, a hydroxyl group and

an -NH₂ group;

- a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
 - 5 ○ a halogen atom,
 - a (C₁-C₃)alkyl group optionally substituted with one or more halogen atoms,
 - a (C₁-C₅)alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C₃-C₅)cycloalkyl group, a
 - 10 heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group,
 - a group -NR₅R_{5'} in which R₅ and R_{5'}, independently, which may be identical or different, represent a substituent chosen from a hydrogen
 - 15 atom, a -CO₂-(C₁-C₃)alkyl group, a (C₃-C₅)cycloalkyl group and a linear or branched (C₁-C₃)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
 - a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an
 - 20 oxygen atom,
 - a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO₂-(C₁-C₄)alkyl group,
 - 25 - a group -NR₆R_{6'} in which R₆ and R_{6'}, which are different, represent a (C₁-C₅)alkyl group and a (C₁-C₅)alkoxy group,
 - R₂ represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;
 - R₄ and R_{4'}, independently, which may be identical or different, represent a
 - 30 hydrogen atom or a (C₁-C₃)alkyl group,
- in the form of the base or of an addition salt with an acid or with a base.

5. The compound of formula (I) as claimed in any one of claims 1 to 4, characterized in that:

- 35 ➤ n represents 0 or 1;
- Y represents a bridged morpholine (a)



(a)

➤ L represents a linker $-\text{CH}_2-\text{CO}-$ such that the carbonyl function is attached to the substituent R_1 , or (C_1-C_2) alkyl, said alkyl being optionally substituted with one or more substituents chosen from a (C_1-C_3) alkyl group;

➤ R_1 represents:


- a linear, branched, cyclic or partially cyclic (C_1-C_5) alkyl group, optionally substituted with one or more substituents chosen from a hydroxyl group and an aryl group,
- 10 - a (C_3-C_6) cycloalkyl group,
- an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group, an $-\text{NH}_2$ group, a urea group of formula $-\text{NH}-\text{CO}-\text{NH}-(\text{C}_1-\text{C}_4)$ alkyl, a morpholinyl group, a group of formula $-\text{SO}_2-(\text{C}_1-\text{C}_5)$ alkyl, a (C_1-C_5) alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
- 15
 - a halogen atom,
 - a hydroxyl group or a (C_1-C_5) alkoxy,
 - a group $-\text{COR}_3$, in which R_3 represents a substituent chosen from a heterocycloalkyl group and a hydroxyl group,
 - 20 ○ a heterocycloalkyl group comprising one or two heteroelements chosen from a nitrogen atom and an oxygen atom,
 - a heteroaryl group optionally substituted with one or more substituents chosen from a halogen atom, a (C_1-C_3) alkyl group, a hydroxyl group and an $-\text{NH}_2$ group,
 - 25 - a heteroaryl group, comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more substituents chosen from:
 - a halogen atom,
 - a (C_1-C_3) alkyl group optionally substituted with one or more halogen atoms,
 - 30 ○ a (C_1-C_5) alkoxy group, optionally substituted with one or more substituents chosen from a halogen atom, a (C_3-C_5) cycloalkyl group, a heteroaryl group optionally substituted with one or more substituents

chosen from a halogen atom, a (C₁-C₃)alkyl group, a hydroxyl group and an -NH₂ group,


- a group -NR₅R_{5'} in which R₅ and R_{5'}, independently, which may be identical or different, represent a substituent chosen from a hydrogen atom, a -CO₂-(C₁-C₃)alkyl group, a (C₃-C₅)cycloalkyl group and a linear or branched (C₁-C₃)alkyl group, said alkyl group being optionally substituted with one or more hydroxyl groups,
 - a pyridine group bearing two linked adjacent groups forming, together with the two carbons that bear them, a heterocycle comprising a nitrogen atom and an oxygen atom,
 - a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group and an acetyl group,
 - a group -NR₆R_{6'} in which R₆ and R_{6'}, which are different, represent a (C₁-C₅)alkyl group and a (C₁-C₅)alkoxy group,
 - R₂ represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;
 - R₄ and R_{4'}, independently, which may be identical or different, represent a hydrogen atom or a (C₁-C₃)alkyl group,
- in the form of the base or of an addition salt with an acid or with a base.

6. The compound of formula (I) as claimed in claim 1 or 2, characterized in that:

- n represents 0 or 1;
- Y represents a bridged morpholine chosen from (b) and (c)



(b)



(c)

- L represents a linker -CH₂-CO- such that the carbonyl function is attached to the substituent R₁, or (C₁-C₂)alkyl, said alkyl being optionally substituted with a hydroxyl group;
- R₁ represents:

- a linear or branched (C₁-C₅)alkyl group, optionally substituted with an aryl group,
 - an aryl group, optionally substituted with one or more substituents chosen from a halogen atom, a hydroxyl group and a (C₁-C₅)alkoxy group, said alkoxy being optionally substituted with one or more substituents chosen from:
 - a group -CONR₄R_{4'} in which R₄ and R_{4'} are as defined below,
 - a group -NR₄R_{4'} in which R₄ and R_{4'} are as defined below,
 - a heteroaryl group comprising one or more heteroatoms chosen from a nitrogen atom, a sulfur atom and an oxygen atom, optionally substituted with one or more (C₁-C₃)alkyl groups, optionally substituted with one or more halogen atoms,
- R₂ represents a hydrogen atom when n represents 1 and a methyl group when n represents 0;
- R₄ and R_{4'}, independently, which may be identical or different, represent a hydrogen atom or a (C₁-C₃)alkyl group,
- in the form of the base or of an addition salt with an acid or with a base.

7. The compound as claimed in any one of claims 1 to 6, characterized in that the linker L represents -CH₂-CO, in the form of the base or of an addition salt with an acid or with a base.

8. The compound as claimed in any one of claims 1 to 7, characterized in that n represents 1, in the form of the base or of an addition salt with an acid or with a base.

9. The compound as claimed in any one of claims 1 to 7, characterized in that n represents 0, in the form of the base or of an addition salt with an acid or with a base.

10. The compound as claimed in any one of claims 1 to 9, characterized in that R₁ represents a heteroaryl group, in the form of the base or of an addition salt with an acid or with a base.

11. The compound as claimed in any one of claims 1 to 9, characterized in that R₁ represents a heterocycloalkyl group comprising one or more heteroatoms chosen from oxygen and nitrogen atoms, said nitrogen atom being optionally substituted with a substituent chosen from a formyl group, an acetyl group and a -CO₂-(C₁-C₄)alkyl group, in the form of the base or of an addition salt with an acid or with a base.

12. The compound as claimed in any one of the preceding claims 1 to 11, characterized in that it is chosen from:

- 1 (8S)-9-(2-Methyl-2-pyrid-4-ylpropyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 2 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 3 (8S)-9-[2-(6-Aminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 4 (8S)-9-[2-(6-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5 (8S)-9-[2-(6-Methylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 6 (8S)-9-[2-(6-Dimethylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 7 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 8 1-[2-(6-Dimethylaminopyrid-3-yl)-2-oxoethyl]-2-(S)-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 9 2-(S)-Methyl-1-[2-(6-methylaminopyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 10 (8S)-1-[2-(4-Methoxyphenyl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-

- azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 11 (S)-1-[2-(6-Aminopyrid-3-yl)-2-oxoethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 12 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 13 2-Methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1-(2-pyrid-3-ylethyl)-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 10 14 (8S)-9-{2-[6-(2-Hydroxyethylamino)pyrid-3-yl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 15 (8S)-9-[2-(5-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 16 2-Methyl-1-[2-(5-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 17 2-Methyl-1-[2-(6-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 20 18 2-Methyl-1-[2-(2-methylpyrid-3-yl)-2-oxoethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 25 19 (8S)-9-[2-(2-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 (8S)-9-[2-(4-Methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-

4-one

- 21 2-Methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-1-(2-oxo-2-pyrid-3-ylethyl)-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 22 (8S)-9-[2-(6-Cyclopropylaminopyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 23 1-Ethyl-3-{4-[2-((S)-8-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)ethyl]phenyl}urea
- 24 1-Ethyl-3-{4-[2-((S)-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-5-oxo-2-trifluoromethyl-2,3-dihydro-5H-imidazo[1,2-a]pyrimidin-1-yl)ethyl]phenyl}urea
- 25 (8S)-9-[2-(4-Methylthiazol-5-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 26 2-Methyl-1-[2-(4-methylthiazol-5-yl)ethyl]-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 27 (8S)-9-[2-(3,5-Dimethyl-1H-pyrazol-4-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 28 1-[2-(3,5-Dimethyl-1H-pyrazol-4-yl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 29 (8S)-9-(3,3-Dimethyl-2-oxobutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 30 1-(3,3-Dimethyl-2-oxobutyl)-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 31 (8S)-9-[2-(6-Amino-5-methylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 32 1-[2-(4-Aminophenyl)ethyl]-2-methyl-7-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-((S)-trifluoromethyl)-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 33 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(6-trifluoromethylpyrid-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5
- 34 (8S)-9-(2-{6-[(2-Hydroxyethyl)methylamino]pyrid-3-yl}-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 35 (8S)-9-[2-(6-Ethoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 10
- 36 (8S)-9-[2-(6-Amino-4,5-dimethylpyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15
- 37 (S)-9-[2-(4-Difluoromethoxyphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 38 (8S)-9-[2-(3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20
- 39 (8S)-9-[2-(4-Methyloxazol-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 40 (S)-9-[2-(3,4-Difluorophenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 25
- 41 (8S)-9-[2-(4-Morpholin-4-ylphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 42 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]benzonitrile
- 43 (8S)-9-[2-(4-Methylthiazol-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5 4-one
- 44 (8S)-9-[2-(5-Chloropyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 45 (8S)-9-[2-(6-Methoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 10 4-one
- 46 (8S)-9-[2-(3-Methylisoxazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 47 (8S)-9-(2-Benzo[1,2,3]thiadiazol-5-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 4-one
- 48 (8S)-9-[2-(2,4-Difluorophenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 4-one
- 49 (8S)-9-(3-Ethyl-3-hydroxypentyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 50 (8S)-9-(3-Hydroxy-3-methylbutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 51 (8S)-9-(1-Methyl-1H-indazol-3-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 25 4-one
- 52 (8S)-9-[2-(2-Cyclopropylmethoxypyrimidin-5-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 4-one

- 53 (8S)-9-[2-(3,5-Dimethylisoxazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 54 (8S)-9-(2-Ethyl-2-hydroxybutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 55 3-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]benzonitrile
- 56 (8S)-9-(3-Methyl-2-oxobutyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 10 57 {5-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]pyrid-2-yl}carbamic acid ethyl ester
- 58 {5-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]pyrid-2-yl}carbamic acid methyl ester
- 15
- 59 (8S)-9-(5-Methyl-[1,2,4]oxadiazol-3-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 60 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(2-trifluoromethylpyrid-3-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20
- 61 (8S)-9-(2-Benzo[1,2,5]thiadiazol-5-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 62 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-oxo-2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 25
- 63 (8S)-9-{2-[6-(2-Fluoroethoxy)pyrid-3-yl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 64 (8S)-9-{2-[3-Fluoro-4-(2-fluoroethoxy)phenyl]-2-oxoethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5 65 (8S)-9-[2-(2-Methoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 66 (8S)-9-[2-(3-Methyl-3H-imidazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 10 67 (8S)-9-(2-Cyclopropyl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 68 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(2-oxo-2-pyrid-2-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 69 (8S)-9-[2-(2-Methyl-2H-pyrazol-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 70 N,N-Dimethyl-2-(4-{2-[(S)-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-5-oxo-2-trifluoromethyl-2,3-dihydro-5H-imidazo[1,2-a]pyrimidin-1-yl]ethyl}phenoxy)acetamide
- 20 71 (8S)-9-[(S)-2-(4-Fluoro-2-methoxyphenyl)-2-hydroxyethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 72 (2S)-1-[2-(4-Hydroxyphenyl)ethyl]-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 25 74 (2S)-1-{2-[4-(2-Dimethylaminoethoxy)phenyl]ethyl}-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 75 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(2-oxo-2-pyrid-4-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

- 76 (S)-1-[2-(4-Methoxyphenyl)ethyl]-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 77 (S)-2-Methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1-(3-phenylpropyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 5 78 (S)-1-{2-[4-(3-Dimethylaminopropoxy)phenyl]ethyl}-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 79 (2S)-1-((S)-2-Hydroxy-2-phenylethyl)-2-methyl-7-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one
- 10 80 (8S)-9-((S)-2-Hydroxy-2-phenylethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 81 (8S)-9-[2-(4-Methoxyphenyl)ethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 82 (8S)-9-((R)-2-Benzo[b]thiophen-2-yl-2-hydroxyethyl)-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 83 (8S)-9-[2-(4-Hydroxyphenyl)ethyl]-2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 84 (8S)-2-(8-Oxa-3-azabicyclo[3.2.1]oct-3-yl)-9-(3-phenylpropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 85 (8S)-2-(3-Oxa-8-azabicyclo[3.2.1]oct-8-yl)-9-(2-oxo-2-pyrid-3-ylethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 89 (S)-9-[2-(1-Acetylpiperid-4-yl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 25 90 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)ethyl]piperidine-1-carbaldehyde
- 91 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-

- 3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]piperidine-1-carboxylic acid ethyl ester
- 92 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(tetrahydropyran-4-yl)ethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5 93 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(tetrahydropyran-4-ylmethyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 94 (8S)-9-(1-Acetylpiperid-4-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 95 4-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-ylmethyl)piperidine-1-carbaldehyde
- 10 96 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(3,3,3-trifluoro-2-hydroxy-2-trifluoromethylpropyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 97 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-(4,4,4-trifluoro-3-hydroxy-3-trifluoromethylbutyl)-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 98 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 99 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)-2-oxoethyl]-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 100 (8S)-9-[2-(1-Hydroxycyclopentyl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 25 101 (8S)-9-(1-Hydroxycyclopentylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 102 (8S)-9-(3,3-Dicyclopropyl-3-hydroxypropyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-


4-one

- 103 (8S)-9-(2,2-Dicyclopropyl-2-hydroxyethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 5 104 (8S)-9-(1-Hydroxycyclopropylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 105 (8S)-9-[2-(1-Hydroxycyclopropyl)ethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 10 106 (8S)-2-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-9-quinolin-5-ylmethyl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 107 (8S)-9-[2-(3-Methylisothiazol-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 15 108 (8S)-9-[2-(4-Methanesulfonylphenyl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 109 (8S)-9-Isoquinolin-5-ylmethyl-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 20 110 (8S)-9-(2-Morpholin-4-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 111 (8S)-9-{2-[4-(2-Morpholin-4-ylethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 25 112 N-Methoxy-N-methyl-2-((S)-8-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetamide
- 113 (8S)-9-(2-Imidazo[1,2-a]pyrid-6-yl-2-oxoethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one


- 114 (8S)-9-[2-(6-Difluoromethoxypyrid-3-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 115 (S)-9-{2-[4-(2-Morpholin-4-yl-2-oxoethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 116 (8S)-9-(1-Methyl-3-trifluoromethyl-1H-pyrazol-4-ylmethyl)-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 117 (8S)-9-{2-[4-(2-Dimethylaminoethoxy)phenyl]ethyl}-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
- 118 4-[2-((S)-8-(1S,4S)-2-Oxa-5-azabicyclo[2.2.1]hept-5-yl-6-oxo-2-trifluoromethyl-3,4-dihydro-2H,6H-pyrimido[1,2-a]pyrimidin-1-yl)acetyl]piperidine-1-carbaldehyde
- 119 (8S)-9-[2-(1-Acetylpiperid-4-yl)-2-oxoethyl]-2-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-8-trifluoromethyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one

in the form of the base or of an addition salt with an acid or with a base.

13. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, comprising the reaction of a compound of formula E




- in which n represents 0 or 1 and R₂ represents a hydrogen atom when n = 1 or a methyl group when n = 0, with a bridged morpholine Y, chosen from (a), (b) and (c) as defined in claim 1, to obtain a compound of formula I



and the alkylation reaction by addition to I of a compound of formula $J = R_1-L-Lg$ in which R_1 and L are as defined in any one of the preceding claims and Lg is a leaving group.


5

14. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, comprising the alkylation reaction of a compound of formula E



in which n represents 0 or 1 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$, by addition of a compound of formula $J = R_1-L-Lg$ in which R_1 and L are as defined in any one of claims 1 to 8 and Lg is a leaving group, to obtain a compound of formula K

10




in which R_1 , R_2 , L and n are as defined in one of claims 1 to 8, and a reaction on a compound K with a compound of formula Y being a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1.


15

15. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is an ethyl group, R_1 is a linear or branched (C_1-C_5)alkyl group substituted with a hydroxyl group, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when $n = 1$ and a methyl group when $n = 0$, comprising a Michael addition reaction of a compound of formula E

20




in which n represents 0 or 1 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$, on a compound of formula $M = CH_2=CH_2-CO_2Alkyl$, to obtain a compound of formula N,




- 5 in which n represents 0 or 1 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$, and Y is a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1,
- and a reaction of alkyl on a compound of formula N with a compound of formula $O = Z-$
- 10 $Mg-X$ in which Z represents a linear or branched alkyl radical and X is a halogen atom.

16. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 12, in which the linker L is a methyl group, R_1 is a linear or branched $(C_1-C_5)alkyl$ group substituted with a hydroxyl group, Y represents a bridged morpholine chosen
- 15 from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when $n = 1$ and a methyl group when $n = 0$, comprising an addition reaction of a compound of formula E




- 20 in which n represents 0 or 1 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$, with a compound of formula $P = X-CH_2-CO_2Alkyl$ with X being a halogen atom, to obtain a compound of formula Q



in which Y is a bridged morpholine chosen from (a), (b) and (c), n represents 0 or 1 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$,


- 5 and an alkylation reaction on a compound of formula Q with a compound of formula $O = Z-Mg-X$ in which Z represents a linear or branched alkyl radical and X is a halogen atom.

17. A process for preparing a compound of formula (I) as claimed in any one of claims
 10 1 to 12, in which the linker L is a methyl group, R_1 is a group $-NR_6R_{6'}$ with R_6 et $R_{6'}$ being either different and representing an alkyl group and an alkoxy group, or R_6 and $R_{6'}$ together forming a monocyclic or bicyclic heterocycloalkyl, Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in claim 1, n represents 1 or 0, and R_2 represents a hydrogen atom when $n = 1$ and a methyl group when $n = 0$, comprising
 15 a hydrolysis reaction of a compound of formula Q



in which Y is a bridged morpholine chosen from (a), (b) and (c), n represents 0 or 1 and R_2 represents a hydrogen atom when $n = 1$ or a methyl group when $n = 0$, to obtain a

- 20 compound of formula S




in which Y represents a bridged morpholine chosen from (a), (b) and (c) as defined in

claim 1, n represents 1 or 0 and R₂ represents a hydrogen atom when n = 1 or a methyl group when n = 0,

and a coupling reaction between a compound of formula S and a compound of formula HNR₆R_{6'} with R₆ and R_{6'} being either different and representing an alkyl group and an alkoxy group, or R₆ and R_{6'} together forming a monocyclic or bicyclic heterocycloalkyl.

18. Compounds of formulae I, N, Q and S:



in which n, R₂ and Y are as defined in claim 1.

19. A medicament, characterized in that it comprises a compound as claimed in any one of claims 1 to 12, or an addition salt of this compound with a pharmaceutically acceptable acid or base.

20. The compound as claimed in any one of claims 1 to 12, as a medicament.

21. A pharmaceutical composition, characterized in that it comprises a compound as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable salt of this compound, and also at least one pharmaceutically acceptable excipient.

22. The use of a compound as claimed in any one of claims 1 to 12, for the preparation of a medicament for treating parasite-induced malaria.

23. The compound as claimed in any one of claims 1 to 12, for its use in the treatment

of malaria induced by all species of *Plasmodium*, such as *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale* and *P. knowlesi*, by all species of *Trypanosoma* and by all species of *Leishmania*, in the treatment of sleeping sickness, the treatment of Chagas disease, the various forms of leishmaniasis and the treatment of other parasitic infections, such

5 as schistosomiasis (bilharzia), toxoplasmosis and coccidiosis.